A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer Richard M. LushAmita PatnaikDaniel SullivanKyriakos P. PapadopoulosMichele Trucksis • Jacqueline McCreaKristine CerchioXiaodong LiMark StrohDiana SelverianKeith Orford • Scot EbbinghausNancy AgrawalMarian IwamotoJohn A. WagnerAnthony Tolcher
Richard M. Lush(Moffitt Cancer Center), Dohme Corp, Marian Iwamoto(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Buckley Sharp, K. Cerchio(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kyriakos P. Papadopoulos(Texas Oncology), Danielle Sullivan(AbbVie (United States)), H. Lee, Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Mark Stroh(CytomX Therapeutics (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Trucksis J. McCrea, X. Li, Nancy Agrawal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keith Orford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Wagner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Diana Selverian(Merck & Co., Inc., Rahway, NJ, USA (United States))
Unknown
January 1, 2012
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k